Tamara Y Milder

8PUBLICATIONS
19CO-AUTHORS
Major global burdens of diseasePharmaceutical delivery technologiesBusiness analyticsAboriginal and Torres Strait Islander medicine and treatmentsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 17, 2026
Hospitalisation Is a Strong Risk Factor for Discontinuation of Sodium-Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes.

|Jul 28, 2026
Trends in publicly subsidized and private access to GLP-1 medicines indicated for type 2 diabetes in Australia, 2020-2025.

|Sep 03, 2024
Use of, time to, and type of first add-on anti-hyperglycaemic therapy to metformin in Australia, 2018-2022.

Tamara Y Milder, Jialing Lin, Sallie-Anne Pearson

|Apr 15, 2024
Geographic variation in sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia.

Juliana de Oliveira Costa, Jialing Lin, Tamara Y Milder

|Aug 07, 2023
'We are somehow fixated on this being a diabetes drug': a qualitative study exploring the views of cardiologists and nephrologists about sodium-glucose cotransporter 2 inhibitor initiation.

Tamara Y Milder, Sophie L Stocker, Melissa T Baysari

Pageof 2

Frequent Collaborators

5 joint publications

Jerry R Greenfield

5 joint publications

Richard O Day

5 joint publications

Michael O Falster

4 joint publications

Sophie L Stocker